Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma SubgroupsStefan G. van Ravensteijn, Ingrid M.E. Desar, Yvonne M.H. Versleijen‐Jonkers et al.|Cancers|2022Cited by 19
Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Jacco J. de Haan et al.|Clinical Cancer Research|2025Cited by 6
Establishment and characterization of the first patient-derived radiation-induced angiosarcoma xenograft model (RT-AS5)Yvonne M.H. Versleijen‐Jonkers, Uta Flucke, Daniel T. von Rhein et al.|Scientific Reports|2023Cited by 3
Which angiosarcoma subtypes may benefit from immunotherapy?Stefan G. van Ravensteijn, Ingrid M.E. Desar, Yvonne M.H. Versleijen‐Jonkers et al.|Journal of Clinical Oncology|2022Cited by 2
Supplementary Figure 3 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker AnalysesStefan G. van Ravensteijn, Ingrid M.E. Desar, Jacco J. de Haan et al.|Unknown|2025Cited by 0